AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29043911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of alcohol
Number of subjects: 50
Study 29043911 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (no alcohol)
Number of subjects: 50
Study 27449273 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 105
Study 27449273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 24507118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Program for Schizophrenia (RECOS), 14 weeks duration
Number of subjects: 16
Study 24507118 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU), no intervention
Number of subjects: 16
Study 22119855 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding CoreValve prosthesis
Number of subjects: 181
Study 20801500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (titrated to a maximum of 7.5 mg twice daily)
Number of subjects: 6558
Study 20801500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6558
Study 20801500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6558
Study 19100377 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution (CS)
Number of subjects: 88
Study 19100377 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW)
Number of subjects: 88
Study 15664719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 12-step participation
Number of subjects: 487
Study 15664719 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased 12-step participation during the first 3 months of treatment
Number of subjects: 487
Study 15664719 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling based on a 12-step model
Number of subjects: 487
Study 15664719 — intervention group
Group type: COMPARATOR
Intervention: Twelve-step group attendance
Number of subjects: 487
Study 12228945 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work after musculoskeletal injury
Number of subjects: 205
Study 12228945 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures
Number of subjects: 205
Study 12228945 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinjury rates
Number of subjects: 205
Study 12228945 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional limitations
Number of subjects: 205
Study 10579471 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL double-strength grapefruit juice
Number of subjects: 10
Study 10579471 — intervention group
Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 10
Study 8636369 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, twice daily)
Number of subjects: 9
Study 1751081 — intervention group
Group type: EXPERIMENTAL
Intervention: Na+ modeling (Na+ = 149 meq/L)
Number of subjects: 39
Study 1751081 — intervention group
Group type: COMPARATOR
Intervention: Standard Na+ dialysate (Na+ = 140 meq/L)
Number of subjects: 39
Study 6749875 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation (PR) exercises via a 30-min self-instructional color videotape.
Number of subjects: 61
Study 6749875 — intervention group
Group type: COMPARATOR
Intervention: Neutral videotape (control group).
Number of subjects: 61
Study 30850677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 102
Study 28951059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education during 1 90-minute grocery store tour
Number of subjects: 132
Study 27440634 — intervention group
Group type: EXPERIMENTAL
Intervention: SAX‐IP approach (short‐axis in‐plane)
Number of subjects: 40
Study 27440634 — intervention group
Group type: COMPARATOR
Intervention: SAX‐OOP approach (short‐axis out‐of‐plane)
Number of subjects: 40
Study 24869973 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD (30 mg/m(2)) and trabectedin (1.1 mg/m(2)) in overweight and obese patients (n = 48)
Number of subjects: 74
Study 24869973 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD (30 mg/m(2)) and trabectedin (1.1 mg/m(2)) in normal weight patients (n = 26)
Number of subjects: 74
Study 22118291 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference arm (medical vs surgical termination of pregnancy)
Number of subjects: 30
Study 22118291 — intervention group
Group type: COMPARATOR
Intervention: Random arm (medical vs surgical termination of pregnancy)
Number of subjects: 30
Study 20951309 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-file F2 ProTaper technique in reciprocating motion (group 2)
Number of subjects: 54
Study 20951309 — intervention group
Group type: COMPARATOR
Intervention: Full range of ProTaper Universal instruments in rotary motion (group 1)
Number of subjects: 54
Study 17331750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk screening for AAA
Number of subjects: 12639
Study 17331750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk screening for AAA
Number of subjects: 12639
Study 17331750 — intervention group
Group type: COMPARATOR
Intervention: High-risk screening
Number of subjects: 12639
Study 16260982 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 95% IAT
Number of subjects: 14
Study 16260982 — intervention group
Group type: COMPARATOR
Intervention: Running at 70% IAT
Number of subjects: 14
Study 12117660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 50 microg b.i.d. only (group F)
Number of subjects: 104
Study 12117660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SCG (2 mg four times daily) and fluticasone propionate powder 50 microg b.i.d. (group FS)
Number of subjects: 104
Study 12117660 — intervention group
Group type: COMPARATOR
Intervention: Combined SCG and fluticasone (group FS)
Number of subjects: 104
Study 10672387 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied over skin areas corresponding to injection sites one hour before nerve blocks, placebo intravenous normal-saline injection 2 minutes before the first nerve block.
Number of subjects: 75
Study 10672387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil 10 micrograms.kg‐1, placebo cream applied.
Number of subjects: 75
Study 10672387 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream and intravenous normal-saline at similar time intervals prior to the nerve blocks.
Number of subjects: 75
Study 7485665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 360
Study 7485665 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about birth control
Number of subjects: 360
Study 7485665 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with partner
Number of subjects: 360
Study 7485665 — intervention group
Group type: EXPERIMENTAL
Intervention: No induced abortion
Number of subjects: 360
Study 7485665 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using condoms due to starting oral contraceptive pill regimens
Number of subjects: 360
Study 1560323 — intervention group
Group type: EXPERIMENTAL
Intervention: CORN/SOY formula
Number of subjects: 45
Study 1560323 — intervention group
Group type: EXPERIMENTAL
Intervention: COCO/SOY formula
Number of subjects: 45
Study 1560323 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 45
Study 1560323 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulas (CORN/SOY and COCO/SOY)
Number of subjects: 45
Study 1560323 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 45
Study 4053698 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg twice daily for seven days
Number of subjects: 73
Study 4053698 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice daily for four days
Number of subjects: 73
Study 31892665 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 280
Study 31892665 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal minitubular microdiscectomy (PMTM)
Number of subjects: 280
Study 31892665 — intervention group
Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 280
Study 31892665 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTM
Number of subjects: 280
Study 29343256 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d green cardamom for 10 weeks
Number of subjects: 80
Study 29343256 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 80
Study 27115400 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-PASS (HIV-Pain and Sadness Study)
Number of subjects: 23
Study 27115400 — intervention group
Group type: COMPARATOR
Intervention: Health education control arm
Number of subjects: 23
Study 26571885 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating-needle therapy combined with rehabilitation training
Number of subjects: 80
Study 26571885 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (control group)
Number of subjects: 80
Study 24012926 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subgenual cingulate gyrus (SCG) with high intensity 130 Hz stimulation for 24 hours
Number of subjects: 6
Study 24012926 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stimulation of the SCG
Number of subjects: 6
Study 24012926 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control condition)
Number of subjects: 6
Study 21466944 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Monitoring (OM) + Recovery Management Checkups (RMC)
Number of subjects: 446
Study 21466944 — intervention group
Group type: COMPARATOR
Intervention: Outcome Monitoring (OM) only
Number of subjects: 446
Study 21466944 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying a person in relapse
Number of subjects: 446
Study 21466944 — intervention group
Group type: EXPERIMENTAL
Intervention: Linking and retaining a person in treatment
Number of subjects: 446
Study 18303458 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy (D)
Number of subjects: 84
Study 18303458 — intervention group
Group type: COMPARATOR
Intervention: Microscopic sequestrectomy (S)
Number of subjects: 84
Study 17108480 — intervention group
Group type: EXPERIMENTAL
Intervention: SEAS.02 exercises
Number of subjects: 48
Study 17108480 — intervention group
Group type: COMPARATOR
Intervention: CONT exercises
Number of subjects: 48
Study 12717124 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl induction regimen with atracurium
Number of subjects: 80
Study 12717124 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl induction regimen without atracurium
Number of subjects: 80
Study 12717124 — intervention group
Group type: EXPERIMENTAL
Intervention: Excellent intubating conditions
Number of subjects: 80
Study 12717124 — intervention group
Group type: EXPERIMENTAL
Intervention: Good intubating conditions
Number of subjects: 80
Study 12717124 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor intubating conditions
Number of subjects: 80
Study 10945384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia with normothermic bypass (group 1)
Number of subjects: 30
Study 10945384 — intervention group
Group type: COMPARATOR
Intervention: Combined antegrade and retrograde cold crystalloid cardioplegia with hypothermic bypass (group 2)
Number of subjects: 30
Study 9447502 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 15
Study 9447502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 15
Study 9447502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7713274 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 DM children
Number of subjects: 36
Study 7713274 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control)
Number of subjects: 36
Study 3128309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ftorafur (1 g/m2/day for 21 days)
Number of subjects: 0
Study 3128309 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil (5-FU) (500 mg/m2/day for 5 days)
Number of subjects: 0
Study 3128309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 28695324 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (56 g daily)
Number of subjects: 84
Study 28695324 — intervention group
Group type: COMPARATOR
Intervention: Cookies (isocaloric control)
Number of subjects: 84
Study 27206386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg pWRG/VEE via IM-EP (N=8)
Number of subjects: 37
Study 27206386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0mg pWRG/VEE via IM-EP (N=9)
Number of subjects: 37
Study 27206386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08mg pWRG/VEE via ID-EP (N=8)
Number of subjects: 37
Study 27206386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3mg pWRG/VEE via ID-EP (N=8)
Number of subjects: 37
Study 27206386 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo via IM-EP (N=4)
Number of subjects: 37
Study 27206386 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo via ID-EP (N=4)
Number of subjects: 37
Study 25514559 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg catechins
Number of subjects: 24
Study 25514559 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg theaflavins
Number of subjects: 24
Study 25514559 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg theaflavins
Number of subjects: 24
Study 25514559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of theaflavins
Number of subjects: 24
Study 22179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory and inhibitory control with attention monitoring
Number of subjects: 128
Study 22179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory and inhibitory control without attention monitoring
Number of subjects: 128
Study 22179720 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 128
Study 22179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory and inhibitory control (both conditions)
Number of subjects: 128
Study 22179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive attention monitoring via EEG
Number of subjects: 128
Study 19423101 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM) of oocytes
Number of subjects: 173
Study 19423101 — intervention group
Group type: COMPARATOR
Intervention: Oocytes matured in vivo
Number of subjects: 173
Study 19423101 — intervention group
Group type: COMPARATOR
Intervention: Germinal vesicle (GV) oocytes
Number of subjects: 173
Study 19423101 — intervention group
Group type: COMPARATOR
Intervention: Meiosis I oocytes
Number of subjects: 173
Study 19062506 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP-A
Number of subjects: 400
Study 15707381 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (n = 13)
Number of subjects: 28
Study 15707381 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 28
Study 11918358 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive tutorial
Number of subjects: 58
Study 11918358 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 58
Study 7851000 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 7851000 — intervention group
Group type: COMPARATOR
Intervention: H2 receptor antagonists
Number of subjects: 0
Study 2472515 — intervention group
Group type: COMPARATOR
Intervention: Synthetic atrial natriuretic peptide (ANP) 1.0, 1.5, and 2.0 micrograms/kg in CRF; 1.0, 1.5, and 3.0 micrograms/kg in NS.
Number of subjects: 0
Study 2472515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31977817 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (70 mg, 140 mg, 210 mg)
Number of subjects: 332
Study 31977817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 30802304 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with oral colistin, tobramycin, and amphotericin B
Number of subjects: 455
Study 30802304 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 455
Study 30802304 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving intravenous cefazolin and metronidazole for perioperative prophylaxis
Number of subjects: 455
Study 30802304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 455
Study 28881549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera vaccine infused with antacids
Number of subjects: 900
Study 28881549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 25447575 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange and rituximab (Group A)
Number of subjects: 500
Study 25447575 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 500
Study 23867152 — intervention group
Group type: EXPERIMENTAL
Intervention: Romanian deadlift (DL) training
Number of subjects: 36
Study 23867152 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated lumbar extension (LUMX) training
Number of subjects: 36
Study 23867152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 20691481 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 310
Study 20691481 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day (for inadequate responders)
Number of subjects: 310
Study 20691481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 20691481 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 310
Study 19420280 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention (n = 12)
Number of subjects: 22
Study 19420280 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 22
Study 16461314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus diclofenac eye drops (group B)
Number of subjects: 60
Study 16461314 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (group A)
Number of subjects: 60
Study 15492131 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP > or = 3.0 mg/L
Number of subjects: 379
Study 15492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 379
Study 15492131 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation
Number of subjects: 379
Study 15492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in waist girth during follow-up
Number of subjects: 379
Study 15492131 — intervention group
Group type: COMPARATOR
Intervention: Decrease in smoking
Number of subjects: 379
Study 11566622 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of IL-1beta (10 ng/ml, once a day for 7 days)
Number of subjects: 0
Study 9783757 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 9323
Study 9783757 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg slow release
Number of subjects: 9323
Study 8181260 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oral pirenzepine
Number of subjects: 6
Study 8181260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2815382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressings until sutures were removed
Number of subjects: 0
Study 2815382 — intervention group
Group type: COMPARATOR
Intervention: Dressings during the first 24 hours after operation only
Number of subjects: 0
Study 942021 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulator
Number of subjects: 60
Study 942021 — intervention group
Group type: COMPARATOR
Intervention: Non-stimulator technique (reliance on paraesthesiae)
Number of subjects: 60
Study 29995697 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT with amlodipine and/or renin angiotensin blockade
Number of subjects: 83
Study 29995697 — intervention group
Group type: COMPARATOR
Intervention: AnonVT with the nonvasodilating beta‐blocker metoprolol
Number of subjects: 83
Study 29995697 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT and AnonVT
Number of subjects: 83
Study 28157412 — intervention group
Group type: EXPERIMENTAL
Intervention: tPAD device
Number of subjects: 6
Study 28157412 — intervention group
Group type: COMPARATOR
Intervention: Oral jet nebulizer
Number of subjects: 6
Study 26053958 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (50-minute motivational interview by a nurse and online self-help material)
Number of subjects: 255
Study 26053958 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 255
Study 26053958 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief advice session)
Number of subjects: 255
Study 23696687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-at-home care
Number of subjects: 53
Study 23696687 — intervention group
Group type: COMPARATOR
Intervention: In-patient hospital care
Number of subjects: 53
Study 22448907 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic management (static or dynamic knee-ankle-foot-orthoses) for 1 year
Number of subjects: 66
Study 22448907 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physical therapy, manual stretching)
Number of subjects: 66
Study 19507268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianwang Buxin Pills (TBPs)
Number of subjects: 39
Study 19507268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17554202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato lycopene extract supplementation
Number of subjects: 56
Study 17554202 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study 15139870 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance (n = 91) with monthly 1 hour/week of psychosocial therapy during the first 6 months
Number of subjects: 179
Study 15139870 — intervention group
Group type: COMPARATOR
Intervention: 180-day detoxification (n = 88) with 3 hours/week of psychosocial therapy and 14 education sessions during the first 6 months
Number of subjects: 179
Study 15139870 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 179